Abstract
QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, showed promising antitumor efficacy in advanced solid tumors including NSCLC in a phase (Ph) I trial. Here, we report the efficacy and safety results from the EGFR mutant cohort of an ongoing Ph II study of QL1706+chemotherapy (chemo)+bevacizumab in patients (pts) with advanced NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have